1,2,4-triazole has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adornato, I; De Luca, L; Gitto, R; Peña-Díaz, S; Ventura, S; Vittorio, S | 1 |
| Bucolo, F; Cuzzocrea, S; De Luca, L; Di Paola, R; Gitto, R; Peña-Díaz, S; Siracusa, R; Ventura, S; Vittorio, S | 1 |
2 other study(ies) available for 1,2,4-triazole and alpha-synuclein
| Article | Year |
|---|---|
Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson's disease.
Topics: alpha-Synuclein; Amines; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Protein Aggregates; Small Molecule Libraries; Structure-Activity Relationship; Triazoles | 2020 |
Discovery of Neuroprotective Agents Based on a 5-(4-Pyridinyl)-1,2,4-triazole Scaffold.
Topics: alpha-Synuclein; Dopaminergic Neurons; Humans; Neuroprotective Agents; Parkinson Disease; Triazoles | 2022 |